Treatment of advanced malignant melanoma with high dose methotrexate and folinic acid rescue

Michael F. Leahy, Hulbert K.B. Silver, Paul Klimo, Thomas C. Hall

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Twenty‐eight patients with advanced malignant melanoma were treated with high dose methotrexate (HDMTX) and folinic acid (FA) rescue. Nineteen patients were treated with 6‐hour infusions and 10 patients with 24‐hour infusions. One patient in the 6‐hour infusion group showed a partial response. In the 24‐hour infusion group there were no responses but there was a significant increase in renal toxicity. It is concluded that HDMTX and FA rescue are not useful agents in the treatment of advanced malignant melanoma.

Original languageEnglish (US)
Pages (from-to)151-156
Number of pages6
JournalMedical and Pediatric Oncology
Volume10
Issue number2
DOIs
StatePublished - Jan 1 1982
Externally publishedYes

Fingerprint

Leucovorin
Methotrexate
Melanoma
Therapeutics
Kidney

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Treatment of advanced malignant melanoma with high dose methotrexate and folinic acid rescue. / Leahy, Michael F.; Silver, Hulbert K.B.; Klimo, Paul; Hall, Thomas C.

In: Medical and Pediatric Oncology, Vol. 10, No. 2, 01.01.1982, p. 151-156.

Research output: Contribution to journalArticle

Leahy, Michael F. ; Silver, Hulbert K.B. ; Klimo, Paul ; Hall, Thomas C. / Treatment of advanced malignant melanoma with high dose methotrexate and folinic acid rescue. In: Medical and Pediatric Oncology. 1982 ; Vol. 10, No. 2. pp. 151-156.
@article{4e08868bdbfb44bc916320d247a09e2d,
title = "Treatment of advanced malignant melanoma with high dose methotrexate and folinic acid rescue",
abstract = "Twenty‐eight patients with advanced malignant melanoma were treated with high dose methotrexate (HDMTX) and folinic acid (FA) rescue. Nineteen patients were treated with 6‐hour infusions and 10 patients with 24‐hour infusions. One patient in the 6‐hour infusion group showed a partial response. In the 24‐hour infusion group there were no responses but there was a significant increase in renal toxicity. It is concluded that HDMTX and FA rescue are not useful agents in the treatment of advanced malignant melanoma.",
author = "Leahy, {Michael F.} and Silver, {Hulbert K.B.} and Paul Klimo and Hall, {Thomas C.}",
year = "1982",
month = "1",
day = "1",
doi = "10.1002/mpo.2950100206",
language = "English (US)",
volume = "10",
pages = "151--156",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Treatment of advanced malignant melanoma with high dose methotrexate and folinic acid rescue

AU - Leahy, Michael F.

AU - Silver, Hulbert K.B.

AU - Klimo, Paul

AU - Hall, Thomas C.

PY - 1982/1/1

Y1 - 1982/1/1

N2 - Twenty‐eight patients with advanced malignant melanoma were treated with high dose methotrexate (HDMTX) and folinic acid (FA) rescue. Nineteen patients were treated with 6‐hour infusions and 10 patients with 24‐hour infusions. One patient in the 6‐hour infusion group showed a partial response. In the 24‐hour infusion group there were no responses but there was a significant increase in renal toxicity. It is concluded that HDMTX and FA rescue are not useful agents in the treatment of advanced malignant melanoma.

AB - Twenty‐eight patients with advanced malignant melanoma were treated with high dose methotrexate (HDMTX) and folinic acid (FA) rescue. Nineteen patients were treated with 6‐hour infusions and 10 patients with 24‐hour infusions. One patient in the 6‐hour infusion group showed a partial response. In the 24‐hour infusion group there were no responses but there was a significant increase in renal toxicity. It is concluded that HDMTX and FA rescue are not useful agents in the treatment of advanced malignant melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0020033267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020033267&partnerID=8YFLogxK

U2 - 10.1002/mpo.2950100206

DO - 10.1002/mpo.2950100206

M3 - Article

VL - 10

SP - 151

EP - 156

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

ER -